In 2011 abiraterone acetate (AA) was approved for the treatment of castrate-resistant metastatic prostate cancer patients who have failed docetaxel chemotherapy.
We report the case of a patient who experienced a confirmed PSA decrease of ≤ 50% after stopping AA, mimicking an antiandrogen withdrawal syndrome.
Written by:
Gauthier H, Bousquet G, Pouessel D, Culine S. Are you the author?
Department of Medical Oncology, Hôpital Saint-Louis, Paris, France.
Reference: Case Rep Oncol. 2012 May;5(2):385-7.
doi: 10.1159/000341564
PubMed Abstract
PMID: 23525261
